To explore the safety and clinical outcomes of laparoscopic enucleation (LapEN) for middle pancreatic tumors adjacent to the main pancreatic duct.

Clinical data of 8 patients who underwent LapEN for benign or borderline tumors closely adjacent to the main pancreatic duct from Jan. 2023 to Dec. 2024 were retrospectively analyzed. Surgical time, intraoperative blood loss, postoperative pancreatic fistula (POPF), and other complications were recorded, and long-term preservation of pancreatic function was evaluated.

All 8 cases were successfully completed laparoscopically. The mean operative time was 125.0±52.98 min, and intraoperative blood loss was 58.7±29.00 ml. All patients developed POPF postoperatively, including 3 cases (37.5%) of grade B fistula, which were successfully managed conservatively or with minimal intervention. No severe POPF or major complications occurred. During the follow-up period (median follow-up of 13.5 months), no tumor recurrence or new-onset diabetes was observed.

With precise surgical techniques, LapEN is safe and effective for benign or borderline tumors adjacent to the main pancreatic duct in the middle pancreas. Despite a relatively high incidence of POPF, clinical management was feasible, and good long-term pancreatic function was preserved.